Divi's Lab Q4 net profit rises 25% to Rs 488 cr, aided by low base

However, the company's earnings showed strong traction in 2020-21 due to a surge in demand for bulk drugs caused by the pandemic

stocks, stock market, m arket, sensex, growth, revenue, earnings, results, Q2,Q1, Q3, Q4, COMPANY, nse, bse,
ANI Business
1 min read Last Updated : May 29 2021 | 4:44 PM IST

Divi's Laboratories on Saturday reported 25 per cent jump in its net profit to Rs 488 crore for the quarter ended March.

It had reported profit after tax of Rs 392 crore in Q4 FY20. Though tax expenses rose from Rs 83 crore to Rs 164 crore in Q4 FY21, total revenues rose 20 per cent on-year to Rs 1,741 crore from Rs 1,453 crore.

The company benefited from a low base in the year-ago quarter which was hit by the Covid-19 national lockdown.

However, the company's earnings showed strong traction in 2020-21 due to a surge in demand for bulk drugs caused by the pandemic.

For the financial year ended March, the company's board of directors approved a final dividend of Rs 20 per share.

Divi's Labs took a capacity expansion with an estimated investment of Rs 400 crore for fast-tracking a customs synthesis project.

A part of the project has been completed and become operational, it said adding that rest of the plan will be completed during early part of the next financial year.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Divi's LaboratoriesQ4 Results

First Published: May 29 2021 | 4:44 PM IST

Next Story